Indication
CDKN2A-p16 Positive
1 clinical trial
1 drug
Clinical trial
Biomarker Modulation by Alpelisib (BYL719) in Transorally Resectable, HPV-Associated HNSCC: A Phase II Window TrialStatus: Terminated, Estimated PCD: 2022-05-24
Drug
Alpelisib1 clinical trial
1 drug